Oliver Miera

Learn More
BACKGROUND Options for mechanical circulatory support as a bridge to heart transplantation in children with severe heart failure are limited. METHODS We conducted a prospective, single-group trial of a ventricular assist device designed specifically for children as a bridge to heart transplantation. Patients 16 years of age or younger were divided into(More)
BACKGROUND The purpose of this study was to evaluate the development of the pulmonary arteries (PAs) after Fontan operation in children at long term. METHODS Thirty-five patients in whom Fontan operation was performed at median age of 4.2 years (range, 1.5 to 16.1 years) underwent angiographic measurements of the central and lower lobe PA diameter before(More)
B cell chronic lymphocytic leukemia (B-CLL) cannot be cured with conventional chemotherapy. This clinical enigma appears to be at least partially due to the fact that B-CLL cells are resistant to programmed cell death (apoptosis) and that they are arrested in G0/G1 phase of the cell cycle. The reasons for the dysregulation of these two key cellular events(More)
BACKGROUND New oral substances such as beraprost, bosentan and sildenafil have proven effective in different forms of pulmonary arterial hypertension (PAH), both alone and in combination with standard treatment such as intravenous and inhaled prostacyclins. However, there are few reports so far on the effect of a combination of exclusively oral substances.(More)
BACKGROUND Pediatric ventricular assist devices may be superior to extracorporeal membrane oxygenation in some respects, especially for medium- and long-term cardiac support. We present our nearly 20-year experience with pediatric ventricular assist devices. METHODS Between 1990 and April 2009, Berlin Heart EXCOR (Berlin Heart AG, Berlin, Germany) was(More)
BACKGROUND Aim of this prospective study was to compare clinical and genetic findings in children with idiopathic or heritable pulmonary arterial hypertension (I/HPAH) with children affected with congenital heart defects associated PAH (CHD-APAH). METHODS Prospectively included were 40 consecutive children with invasively diagnosed I/HPAH or CHD-APAH and(More)
Bosentan, ein dualer Endothelin-Rezeptor-Antagonist, ist bei der Behandlung der idiopatischen (primären) Form der pulmonalarteriellen Hypertonie (PAH) als effektive Therapieform eingesetzt worden. Wir haben Bosentan im Rahmen eines Heilversuches bei Säuglingen und Kleinkindern eingesetzt, welche bereits präoperativ einen erhöhten Lungengefäßwiderstand und(More)
BACKGROUND Inadequate cyclosporine (CsA) blood levels are a major risk factor for acute rejection in transplant recipients. The CsA trough level (C0 level) measured just before the next dose is commonly used to adjust the oral dosage. However, the 2-hour post-CsA dose concentration (C2 level) is favored as the best single-point correlate of CsA(More)
The 2015 European Guidelines on Diagnosis and Treatment of Pulmonary Hypertension are also valid for Germany. The guidelines contain detailed recommendations for different forms of PH, and specifically address PH associated with congenital heart disease (CHD). However, the practical implementation of the European Guidelines in Germany requires the(More)
BACKGROUND The objective of this prospective study was to assess the efficacy of exercise training as add-on to medical therapy in patients with congenital heart disease associated pulmonary arterial hypertension (CHD-APAH). METHODS Patients with invasively confirmed CHD-APAH received in-hospital exercise training for 3 weeks and continued at home.(More)